Literature DB >> 15703931

Does diabetes mellitus influence the efficacy of FDG-PET in the diagnosis of cervical cancer?

Yu-Chen Chang1, Tzu-Chen Yen, Koon-Kwan Ng, Lai-Chu See, Chyong-Huey Lai, Ting-Chang Chang, Chien-Sheng Tsai, Ji-Hong Hong, Swei Hsueh, Hung-Hsueh Chou.   

Abstract

PURPOSE: Compared with computed tomography (CT) and magnetic resonance imaging (MRI), positron emission tomography (PET) may have additional value in the assessment of primary and recurrent cervical cancer. However, the degree of tumour uptake of (18)F-2-fluoro-2-deoxy-D: -glucose (FDG) uptake is sometimes influenced by diabetes mellitus (DM). Therefore, we conducted this prospective study to compare the diagnostic ability of FDG-PET in patients with cervical cancer complicated by DM and those without DM.
METHODS: Patients with untreated locally advanced primary or clinically curable recurrent cervical carcinoma were enrolled. Both FDG-PET and MRI/CT scans were performed within 2 weeks. Patients were categorised into the following groups: hyperglycaemic DM (fasting blood sugar >126 mg/dl), euglycaemic DM and non-DM. The lesions were confirmed histologically or by clinical follow-up. The receiver operating characteristic curve method, with calculation of the area under the curve (AUC), was used to evaluate the discriminative power.
RESULTS: From February 2001 to January 2003, 219 patients (75 with primary and 144 with recurrent cervical cancer) were eligible for analysis. Sixteen had hyperglycaemic DM, 12 had euglycaemic DM and 191 were in the non-DM group. The diagnostic power of PET in the hyperglycaemic DM, euglycaemic DM and non-DM groups did not differ significantly with regard to the identification of either metastatic lesions (AUC, 0.967/0.947/0.925, P>0.05) or primary tumours/local recurrence (AUC, 0.950/0.938/0.979, P>0.05). Considering all DM patients, PET showed a significantly higher detection power than MRI/CT scans in respect of metastatic lesions (AUC=0.956 vs 0.824, P=0.012).
CONCLUSION: In comparison with its accuracy in non-DM patients, the accuracy of PET in cervical cancer patients with mild to moderate DM was not significantly reduced.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15703931     DOI: 10.1007/s00259-004-1744-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  22 in total

1.  Effect of hyperglycemia on tumoral uptake of F-18 FDG.

Authors:  Neena N Dave; Rohit Walia; Merrick Shor; Amjad Ali
Journal:  Clin Nucl Med       Date:  2002-09       Impact factor: 7.794

2.  The impact of image fusion in resolving discrepant findings between FDG-PET and MRI/CT in patients with gynaecological cancers.

Authors:  Cheng-Chien Tsai; Chien-Sheng Tsai; Koon-Kwan Ng; Chyong-Huey Lai; Swei Hsueh; Pan-Fu Kao; Ting-Chang Chang; Ji-Hong Hong; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-08-21       Impact factor: 9.236

3.  Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma.

Authors:  R L Wahl; C A Henry; S P Ethier
Journal:  Radiology       Date:  1992-06       Impact factor: 11.105

Review 4.  Targeting of the insulin-regulatable glucose transporter (GLUT-4).

Authors:  D E James
Journal:  Biochem Soc Trans       Date:  1994-08       Impact factor: 5.407

5.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1983-09       Impact factor: 11.105

6.  FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies.

Authors:  C G Diederichs; L Staib; G Glatting; H G Beger; S N Reske
Journal:  J Nucl Med       Date:  1998-06       Impact factor: 10.057

Review 7.  The new diagnostic criteria for diabetes: the impact on management of diabetes and macrovascular risk factors.

Authors:  A L Peters; D L Schriger
Journal:  Am J Med       Date:  1998-07-06       Impact factor: 4.965

8.  18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression.

Authors:  Tzu-Chen Yen; Lai-Chu See; Chyong-Huey Lai; Chou Wu Yah-Huei; Koon-Kwan Ng; Shih-Ya Ma; Wuu-Jyh Lin; Jenn-Tzong Chen; Wen-Jie Chen; Chiung-Ru Lai; Swei Hsueh
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

9.  Influence of the blood glucose concentration on FDG uptake in cancer--a PET study.

Authors:  P Lindholm; H Minn; S Leskinen-Kallio; J Bergman; U Ruotsalainen; H Joensuu
Journal:  J Nucl Med       Date:  1993-01       Impact factor: 10.057

10.  Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography.

Authors:  Chyong-Huey Lai; Kuan-Gen Huang; Lai-Chu See; Tzu-Chen Yen; Chien-Sheng Tsai; Ting-Chang Chang; Hung-Hsueh Chou; Koon-Kwan Ng; Swei Hsueh; Ji-Hong Hong
Journal:  Cancer       Date:  2004-02-01       Impact factor: 6.860

View more
  6 in total

1.  Altered FDG uptake patterns in pediatric lymphoblastic lymphoma patients receiving induction chemotherapy that includes very high dose corticosteroids.

Authors:  Susan E Sharp; Michael J Gelfand; Michael J Absalon
Journal:  Pediatr Radiol       Date:  2011-09-01

2.  Optimization of whole-body positron emission tomography imaging by using delayed 2-deoxy-2-[F-18]fluoro-D: -glucose Injection following I.V. Insulin in diabetic patients.

Authors:  Eric Turcotte; Michel Leblanc; André Carpentier; François Bénard
Journal:  Mol Imaging Biol       Date:  2006 Nov-Dec       Impact factor: 3.488

3.  Influence of Diabetes on the Interpretation of PET Scans in Patients With Esophageal Cancer.

Authors:  Michael Haley; Andre Konski; Tianyu Li; Jonathan D Cheng; Alan Maurer; Oleh Haluszka; Walter Scott; Neal J Meropol; Steven J Cohen; Gary Freedman
Journal:  Gastrointest Cancer Res       Date:  2009-07

4.  Does diabetes mellitus influence standardized uptake values of fluorodeoxyglucose positron emission tomography in colorectal cancer?

Authors:  Da Yeon Oh; Ji Won Kim; Seong-Joon Koh; Mingoo Kim; Ji Hoon Park; Su Yeon Cho; Byeong Gwan Kim; Kook Lae Lee; Jong Pil Im
Journal:  Intest Res       Date:  2014-04-29

5.  Impact of Plasma Glucose Level at the Time of Fluorodeoxyglucose Administration on the Accuracy of FDG-PET/CT in the Diagnosis of Pancreatic Lesions.

Authors:  Alireza Hamidian Jahromi; Mohammad Kazem Fallahzadeh; Amol Takalkar; Jean Sheng; Gazi Zibari; Hosein Shokouh Amiri
Journal:  Int J Endocrinol Metab       Date:  2014-10-01

6.  Prognostic value of pretreatment standardized uptake value of F-18-fluorodeoxyglucose PET in patients with gastric cancer: a meta-analysis.

Authors:  Zhonghua Wu; Junhua Zhao; Peng Gao; Yongxi Song; Jingxu Sun; Xiaowan Chen; Bin Ma; Zhenning Wang
Journal:  BMC Cancer       Date:  2017-04-17       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.